DOP059 Reduction of fecal calprotectin levels and relationship to clinical parameters in the phase 2 study of laquinimod for the treatment of active moderate to severe Crohn's disease

DOP059 Reduction of fecal calprotectin levels and relationship to clinical parameters in the phase 2 study of laquinimod for the treatment of active moderate to severe Crohn’s disease G. D’Haens1 *, W.J. Sandborn2, P. Rutgeerts3, J.F. Colombel4, K. Brown5, A. Haviv6, H. Barkay7, A. Sakov7, B. Feagan8. 1University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 2University of California, UCSD Inflammatory Bowel Disease Center, San Diego CA, United States, 3Catholic University of Leuven, Department of Internal Medicine and Endoscopy, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, 5Teva Pharmaceuticals, Clinical Development Research and Development, Frazer, United States, 6Chiasma Pharm, Formerly of Teva Pharmaceuticals, Jerusalem, Israel, 7Teva Pharmaceuticals, Biostatistics Research and Development, Netanya, Israel, 8University of Western Ontario, Robarts Clinical Trials Robarts Research Institute, Ontario, Canada